

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PAPER NUMBER

ATTORNEY DOCKET NO. CONFIRMATION NO. FIRST NAMED INVENTOR APPLICATION NO. FILING DATE 1581.0900000/RWE/MTT 2729 10/070,764 03/12/2002 John Andrew Chaddock EXAMINER 10/04/2004 26111 7590 STERNE, KESSLER, GOLDSTEIN & FOX PLLC DEVI, SARVAMANGALA J N

STERNE, KESSLER, GOLDSTEIN & FOX PLLC 1100 NEW YORK AVENUE, N.W. WASHINGTON, DC 20005

1645
DATE MAILED: 10/04/2004

ART UNIT

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
Office Action Summary	10/070,764	CHADDOCK ET AL.	
	Examiner	Art Unit	
	S. Devi, Ph.D.	1645	
The MAILING DATE of this communication a Period for Reply	appears on the cover sheet	with the correspondence address	
A SHORTENED STATUTORY PERIOD FOR REF THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a r - If NO period for reply is specified above, the maximum statutory perion. - Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the material patent term adjustment. See 37 CFR 1.704(b).	N. 1.136(a). In no event, however, may reply within the statutory minimum of the dwill apply and will expire SIX (6) Mount of the cause the application to become	ireply be timely filed irty (30) days will be considered timely. NTHS from the mailing date of this communication.	
Status			
1)⊠ Responsive to communication(s) filed on			
	his action is non-final.		ē
3) Since this application is in condition for allow		tters, prosecution as to the merits is	
closed in accordance with the practice unde			
Disposition of Claims			
4) Claim(s) 22-40 is/are pending in the applicate 4a) Of the above claim(s) is/are withdress 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 22-40 are subject to restriction and/	rawn from consideration.		
Application Papers			
9) The specification is objected to by the Examination 10) The drawing(s) filed on is/are: a) and a complete and a compl	ccepted or b) objected to ne drawing(s) be held in abeya ection is required if the drawin	nce. See 37 CFR 1.85(a). g(s) is objected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreignal All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bure * See the attached detailed Office action for a list	nts have been received. nts have been received in a iority documents have been au (PCT Rule 17.2(a)).	Application No received in this National Stage	
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date U.S. Patent and Trademark Office	Paper No 5) Notice of 6) Other:	Summary (PTO-413) s)/Mail Date nformal Patent Application (PTO-152) 	
PTOL-326 (Rev. 1-04) Office A	Action Summary	Part of Paper No./Mail Date 092004	

Serial No. 10/070,764

Art Unit: 1645

Lack of Unity of Invention(s)

1) Claims 1-21 have been canceled.

New claims 22-40 have been added.

Claims 22-40 are pending and are under prosecution.

- 2) The instant inventions lack unity under PCT Rule 13.1 and 13.2:
 - I. Claims 22-30 and 37-40, drawn to a method of reducing toxicity of a clostridial toxin derivative preparation by contacting with a ligand; and a method of removing a clostridial toxin from a preparation containing the toxin and a derivative of the toxin using a first and a second ligand, classified in class 530, subclass 413
 - II. Claims 31 and 32, drawn to an affinity chromatography column comprising a ligand that selectively binds to toxin, but not to the toxin derivative, classified in class 436, subclass 535
 - III. Claims 33, drawn to a clostridial toxin derivative preparation comprising 1-100 ppm clostridial toxin per toxin derivative, classified in class 424, subclass 832
 - IV. Claims 34-36, drawn to a composition comprising a clostridial toxin derivative, a pharmaceutically acceptable carrier and a ligand that selectively binds to the toxin, classified in class 514, subclass 2
- 3) Groups I-IV are drawn to multiple inventions that lack unity of inventions. The special technical feature of the first claimed method is a method of reducing toxicity of a clostridial toxin derivative preparation by contacting with a ligand. The special technical feature of inventions II, III and IV are an affinity chromatography column comprising a ligand that selectively binds to toxin, but not to the toxin derivative; a clostridial toxin derivative preparation comprising 1-100 ppm clostridial toxin per toxin derivative; and a composition comprising a clostridial toxin derivative, a pharmaceutically acceptable carrier and a ligand that selectively binds to the toxin respectively. However, these special technical features do not define over the prior art, since the prior art already taught the method, the column and the preparation. For instance, Gimenez *et al.* (*J. Protein Chem.* 12: 351-363, 1993) taught a method of contacting a type A clostridial neurotoxin contained in a buffer and digested with pepsin (i.e., a clostridial toxin derivative preparation) with cationic DEAE-Sephadex or Mono Q in a column wherein the 42K fragments (i.e., toxin derivatives) did not bind to

Serial No. 10/070,764

Art Unit: 1645

DEAE-Sephadex or Mono Q, but the 147 kD toxin did bind (see sections 3.3 and 2.5; Figure 3; and paragraph bridging pages 358 and 359). Gimenez *et al.* taught the chromatographically purified clostridial neurotoxin fragments (i.e., derivatives) that were dialyzed, ammonium sulfate-precipitated, and further dialyzed to obtain purified fragments (see section 3.5). The chromatographic elution results depicted in Figure 5D shows that the toxin fragments were free of the 147 kD toxin. Therefore, inventions I, II, II and IV do not share significant reagents or compositions, and/or methods steps.

- 4) Papers related to this application may be submitted to Group 1600, AU 1645 by facsimile transmission. Papers should be transmitted via the PTO Fax Center, which receives transmissions 24 hours a day and 7 days a week. The transmission of such papers by facsimile must conform with the notice published in the Official Gazette, 1096 OG 30, November 15, 1989. The RightFax number for submission of amendments, responses or papers is (703) 872-9306.
- Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAG or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.Mov. Should you have questions on access to the Private PAA system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
- Any inquiry concerning this communication or earlier communications from the Examiner should be directed to S. Devi, Ph.D., whose telephone number is (571) 272-0854. A message may be left on the Examiner's voice mail system. The Examiner can normally be reached on Monday to Friday from 7.15 a.m. to 4.15 p.m. except one day each bi-week, which would be disclosed on the Examiner's voice mail system.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Lynette Smith, can be reached on (571) 272-0864.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.

September, 2004

S. DEVI, PH.D.
PRIMARY EXAMINER